Gland Pharma Limited (NSE:GLAND)
India
· Delayed Price · Currency is INR 1,648.20
+14.60 (0.89%)
Jun 6, 2025, 12:30 PM IST
Gland Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Revenue | 56,165 | 56,647 | 36,246 | 44,007 | 34,629 | Upgrade
|
| Revenue Growth (YoY) | -0.85% | 56.28% | -17.64% | 27.08% | 31.51% | Upgrade
|
| Cost of Revenue | 22,895 | 25,539 | 18,595 | 22,494 | 16,097 | Upgrade
|
| Gross Profit | 33,270 | 31,108 | 17,651 | 21,513 | 18,532 | Upgrade
|
| Selling, General & Admin | 14,016 | 12,668 | 4,047 | 3,397 | 3,122 | Upgrade
|
| Other Operating Expenses | 6,565 | 4,895 | 3,271 | 3,009 | 2,385 | Upgrade
|
| Operating Expenses | 24,359 | 21,223 | 8,807 | 7,513 | 6,498 | Upgrade
|
| Operating Income | 8,911 | 9,885 | 8,844 | 14,000 | 12,034 | Upgrade
|
| Interest Expense | -420 | -217.9 | -62.87 | -34.02 | -29.11 | Upgrade
|
| Interest & Investment Income | - | 1,506 | 1,794 | 1,386 | 859.49 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 106.05 | 571.45 | 792.05 | 405.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,136 | 9.1 | -1.07 | -2.85 | 77.77 | Upgrade
|
| EBT Excluding Unusual Items | 10,627 | 11,288 | 11,146 | 16,142 | 13,348 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.48 | 28.48 | 44.89 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 2.49 | -0.81 | -1.78 | 0.24 | Upgrade
|
| Asset Writedown | - | - | -63.32 | - | - | Upgrade
|
| Other Unusual Items | - | - | -564.61 | - | - | Upgrade
|
| Pretax Income | 10,627 | 11,325 | 10,546 | 16,186 | 13,348 | Upgrade
|
| Income Tax Expense | 3,641 | 3,601 | 2,735 | 4,069 | 3,378 | Upgrade
|
| Net Income | 6,985 | 7,725 | 7,810 | 12,117 | 9,970 | Upgrade
|
| Net Income to Common | 6,985 | 7,725 | 7,810 | 12,117 | 9,970 | Upgrade
|
| Net Income Growth | -9.57% | -1.10% | -35.54% | 21.54% | 29.00% | Upgrade
|
| Shares Outstanding (Basic) | 165 | 165 | 165 | 164 | 158 | Upgrade
|
| Shares Outstanding (Diluted) | 165 | 165 | 165 | 165 | 158 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.03% | 0.09% | 3.96% | 2.15% | Upgrade
|
| EPS (Basic) | 42.40 | 46.90 | 47.44 | 73.81 | 63.07 | Upgrade
|
| EPS (Diluted) | 42.40 | 46.89 | 47.43 | 73.64 | 62.99 | Upgrade
|
| EPS Growth | -9.58% | -1.14% | -35.59% | 16.91% | 26.29% | Upgrade
|
| Free Cash Flow | 5,302 | 6,069 | 1,430 | 2,794 | 3,762 | Upgrade
|
| Free Cash Flow Per Share | 32.18 | 36.84 | 8.69 | 16.98 | 23.77 | Upgrade
|
| Dividend Per Share | 18.000 | 20.000 | - | - | - | Upgrade
|
| Dividend Growth | -10.00% | - | - | - | - | Upgrade
|
| Gross Margin | 59.24% | 54.92% | 48.70% | 48.88% | 53.52% | Upgrade
|
| Operating Margin | 15.87% | 17.45% | 24.40% | 31.81% | 34.75% | Upgrade
|
| Profit Margin | 12.44% | 13.64% | 21.55% | 27.53% | 28.79% | Upgrade
|
| Free Cash Flow Margin | 9.44% | 10.71% | 3.95% | 6.35% | 10.86% | Upgrade
|
| EBITDA | 12,689 | 13,138 | 10,310 | 15,102 | 13,020 | Upgrade
|
| EBITDA Margin | 22.59% | 23.19% | 28.44% | 34.32% | 37.60% | Upgrade
|
| D&A For EBITDA | 3,779 | 3,253 | 1,466 | 1,101 | 985.75 | Upgrade
|
| EBIT | 8,911 | 9,885 | 8,844 | 14,000 | 12,034 | Upgrade
|
| EBIT Margin | 15.87% | 17.45% | 24.40% | 31.81% | 34.75% | Upgrade
|
| Effective Tax Rate | 34.27% | 31.79% | 25.94% | 25.14% | 25.31% | Upgrade
|
| Revenue as Reported | 58,301 | 58,350 | 38,651 | 46,246 | 35,977 | Upgrade
|
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.